Table 3 Class of biologics taken in the BMD <70 % of YAM and BMD ≥70 % of YAM groups
From: Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics
|  | BMD <70 % of YAM | BMD ≥70 % of YAM |
|---|---|---|
TNFα inhibitor | 26 | 66 |
Tocilizumab | 6 | 16 |
Abatacept | 3 | 9 |
Switch biologics | 22 | 38 |